Eli Lilly's Potential Blockbuster Drug Could Revolutionize the Insulin Market
Eli Lilly's Potential Blockbuster Drug Breakthrough Sparks Investor Excitement
This winner can't stop winning. Eli Lilly (NYSE: LLY) can't stop grabbing headlines. The pharmaceutical company has made quite a bit of noise over the past few years thanks to notable clinical and regulatory progress.
Moving toward a showdown with its biggest rival
Eli Lilly has long been a leader in the insulin market. The drugmaker has been developing a once-weekly insulin product called efsitora alfa.
Eli Lilly just reported positive phase 3 results for this investigational therapy. Efsitora alfa was pitted against daily insulin in treating type 2 diabetes patients.
However, Eli Lilly is trailing its longtime rival Novo Nordisk here.
There are too many reasons to buy
- 31% of diabetes patients use insulin therapy.
- Eli Lilly's addressable market with efsitora alfa will be large.
- Medicines such as cancer drug Verzenio and immunosuppressant Taltz made an impact.
- Mounjaro in obesity could become the best-selling product in the history of the industry.
While efsitora alfa looks promising, it will be a relatively small part of Eli Lilly's giant growth machine.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.